242 related articles for article (PubMed ID: 31780742)
1. Tsc1-mTORC1 signaling controls striatal dopamine release and cognitive flexibility.
Kosillo P; Doig NM; Ahmed KM; Agopyan-Miu AHCW; Wong CD; Conyers L; Threlfell S; Magill PJ; Bateup HS
Nat Commun; 2019 Nov; 10(1):5426. PubMed ID: 31780742
[TBL] [Abstract][Full Text] [Related]
2. Corticostriatal Transmission Is Selectively Enhanced in Striatonigral Neurons with Postnatal Loss of Tsc1.
Benthall KN; Ong SL; Bateup HS
Cell Rep; 2018 Jun; 23(11):3197-3208. PubMed ID: 29898392
[TBL] [Abstract][Full Text] [Related]
3. Loss of Tsc1 from striatal direct pathway neurons impairs endocannabinoid-LTD and enhances motor routine learning.
Benthall KN; Cording KR; Agopyan-Miu AHCW; Wong CD; Chen EY; Bateup HS
Cell Rep; 2021 Aug; 36(6):109511. PubMed ID: 34380034
[TBL] [Abstract][Full Text] [Related]
4. Tsc1 haploinsufficiency in Nkx2.1 cells upregulates hippocampal interneuron mTORC1 activity, impairs pyramidal cell synaptic inhibition, and alters contextual fear discrimination and spatial working memory in mice.
Haji N; Riebe I; Aguilar-Valles A; Artinian J; Laplante I; Lacaille JC
Mol Autism; 2020 May; 11(1):29. PubMed ID: 32375878
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
6. The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.
Zhang B; Zou J; Han L; Beeler B; Friedman JL; Griffin E; Piao YS; Rensing NR; Wong M
Epilepsia; 2018 Sep; 59(9):1796-1806. PubMed ID: 30079598
[TBL] [Abstract][Full Text] [Related]
7. Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations.
Aksoylu IS; Martin P; Robert F; Szkop KJ; Redmond NE; Bhattacharyya S; Wang J; Chen S; Beauchamp RL; Nobeli I; Pelletier J; Larsson O; Ramesh V
Mol Autism; 2023 Oct; 14(1):39. PubMed ID: 37880800
[TBL] [Abstract][Full Text] [Related]
8. Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex.
Karalis V; Caval-Holme F; Bateup HS
Nat Commun; 2022 Aug; 13(1):4665. PubMed ID: 35945201
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice.
Koike-Kumagai M; Fujimoto M; Wataya-Kaneda M
Neuropharmacology; 2022 Nov; 218():109203. PubMed ID: 35931213
[TBL] [Abstract][Full Text] [Related]
10. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
[TBL] [Abstract][Full Text] [Related]
11. Sensitive period for rescuing parvalbumin interneurons connectivity and social behavior deficits caused by TSC1 loss.
Amegandjin CA; Choudhury M; Jadhav V; Carriço JN; Quintal A; Berryer M; Snapyan M; Chattopadhyaya B; Saghatelyan A; Di Cristo G
Nat Commun; 2021 Jun; 12(1):3653. PubMed ID: 34135323
[TBL] [Abstract][Full Text] [Related]
12. The non-essential TSC complex component TBC1D7 restricts tissue mTORC1 signaling and brain and neuron growth.
Schrötter S; Yuskaitis CJ; MacArthur MR; Mitchell SJ; Hosios AM; Osipovich M; Torrence ME; Mitchell JR; Hoxhaj G; Sahin M; Manning BD
Cell Rep; 2022 May; 39(7):110824. PubMed ID: 35584673
[TBL] [Abstract][Full Text] [Related]
13. mTORC1 activation is not sufficient to suppress hepatic PPARα signaling or ketogenesis.
Selen ES; Wolfgang MJ
J Biol Chem; 2021 Jul; 297(1):100884. PubMed ID: 34146544
[TBL] [Abstract][Full Text] [Related]
14. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
Lam HC; Siroky BJ; Henske EP
Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
[TBL] [Abstract][Full Text] [Related]
15. A Farnesyltransferase Inhibitor Restores Cognitive Deficits in
Sugiura H; Shimada T; Moriya-Ito K; Goto JI; Fujiwara H; Ishii R; Shitara H; Taya C; Fujii S; Kobayashi T; Hino O; Worley PF; Yamagata K
J Neurosci; 2022 Mar; 42(12):2598-2612. PubMed ID: 35121635
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic Screen with TSC-Deficient Neurons Reveals Heat-Shock Machinery as a Druggable Pathway for mTORC1 and Reduced Cilia.
Di Nardo A; Lenoël I; Winden KD; Rühmkorf A; Modi ME; Barrett L; Ercan-Herbst E; Venugopal P; Behne R; Lopes CAM; Kleiman RJ; Bettencourt-Dias M; Sahin M
Cell Rep; 2020 Jun; 31(12):107780. PubMed ID: 32579942
[TBL] [Abstract][Full Text] [Related]
17. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies.
McEneaney LJ; Tee AR
Adv Genet; 2019; 103():91-118. PubMed ID: 30904097
[TBL] [Abstract][Full Text] [Related]
18. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
19. Tsc2 mutation rather than Tsc1 mutation dominantly causes a social deficit in a mouse model of tuberous sclerosis complex.
Kashii H; Kasai S; Sato A; Hagino Y; Nishito Y; Kobayashi T; Hino O; Mizuguchi M; Ikeda K
Hum Genomics; 2023 Feb; 17(1):4. PubMed ID: 36732866
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
